Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical prediction of opioid use disorder in chronic pain patients: a cohort-retrospective study with a pharmacogenetic approach.

Minerva anestesiologica - 1 May 2024

Escorial Mónica, Muriel Javier, Agulló Laura, Zandonai Thomas, Margarit César, Morales Domingo, Peiró Ana M

Abstract excerpt

BACKGROUND: Opioids are widely used in chronic non-cancer pain (CNCP) management. However, they remain controversial due to serious risk of causing opioid use disorder (OUD). Our main aim was to develop a predictive model for future clinical translation that include pharmacogenetic markers. METHODS: An observational study was conducted in 806 pre-screened Spanish CNCP patients, under long-term use of opioids, to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Analgesics, Opioid
Share to Catechol O-Methyltransferase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chronic Pain

Share to Cohort Studies

Share to Cytochrome P-450 CYP2D6

Share to Opioid-Related Disorders

Share to Pharmacogenetics

Share to Receptors, Opioid, mu

Source

Identifiers

PMID: 38619184
DOI: 10.23736/S0375-9393.24.17864-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical prediction of opioid use disorder in chronic pain patients: a cohort-retrospective study with a pharmacogenetic approach.PMID 38619184Read ↗

Pain polymorphisms and opioids: An evidence based reviewSemantic proximity Read ↗

Oxycodone/naloxone versus Tapentadol in real-world chronic non-cancer pain management: a prospective controlled and pharmacogenetic studySemantic proximity Read ↗

Review of Opioid Pharmacogenetics and Considerations for Pain ManagementSemantic proximity Read ↗

OPRM1 influence on and effectiveness of an individualized treatment plan for prescription opioid use disorder patients.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy.Semantic proximity Read ↗

Fundamental Considerations for GeneticallyGuided Pain Management with Opioids Based on CYP2D6 and OPRM1 PolymorphismsSemantic proximity Read ↗

The value of CYP2D6 and OPRM1 pharmacogenetic testing for opioid therapy.Semantic proximity Read ↗

Pharmacogenomics and Patient Treatment Parameters to Opioid Treatment in Chronic Pain: A Focus on Morphine, Oxycodone, Tramadol, and Fentanyl.Semantic proximity Read ↗

ABCB1, SLC22A1, COMT, and OPRM1 genotypes: Study of their influence on plasma methadone levels and clinical response to methadone maintenance treatment in opioid use disorder.Semantic proximity Read ↗

Reviewing pharmacogenetics to advance precision medicine for opioidsSemantic proximity Read ↗

CYP2D6 phenotypes and opioid metabolism: the path to personalized analgesia.Semantic proximity Read ↗

Sex Bias and Genotype Influence on Opioid Safety Profile in Chronic Low Back Pain.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.